EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of Efficacy of Neoadjuvant Immunochemotherapy for Cervical Metastatic Squamous Cell Carcinoma of Unknown Primary

Xianlu Gao iD, Shuwen Fu, Chulin Yang, Wenmei Jiang, Jiadong Liang, Ruiyu Li, Shida Yan, Mingyuan Du, Shiyan Yang, Quan Zhang, Shuwei Chen

Cancer Medicine · 2025

DOI: 10.1002/cam4.70869 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Xianlu Gao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Uterine Cervical Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aims to evaluate the antitumor activity of neoadjuvant immunochemotherapy in patients with cervical metastatic squamous cell carcinoma of unknown primary (CMSCCUP), providing a new idea for its treatment.

Method

We retrospectively examined the medical records from Sun Yat‐sen University Cancer Center to identify patients with CMSCCUP from July 2020 to November 2023. CMSCCUP's diagnoses are based on the results of biopsy and imaging examination. All patients received PD‐1 inhibitors combined with chemotherapy: paclitaxel (Albumin‐bound) 260 mg/m 2 and cisplatin 60 mg/m 2 every 3 weeks for two or more cycles as their initial treatment. Clinical response after neoadjuvant immunochemotherapy was assessed using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Surgery, radiotherapy, or chemoradiotherapy was performed subsequently based on the imaging evaluation results. Outcomes included overall survival (OS) and disease‐free survival (DFS).

Result

After neoadjuvant immunochemotherapy, the objective response rate (ORR) was 84.2%; complete response (CR), partial response (PR), and stable disease (SD) were 36.8%, 47.4%, and 15.8%, respectively. Of the 9 patients (42.9%) who underwent surgery after neoadjuvant immunochemotherapy, 7 (77.8%) achieved pathological complete response (pCR). No severe treatment‐related adverse events occurred. The most common treatment‐related adverse events were Grade 1–2 fatigue (11/14, 78.6%), decreased appetite (11/15, 73.3%), and increased aspartate transaminase (12/20, 60.0%). One (1/20, 5.0%) patient experienced Grade 3 anemia. The 2‐year overall survival (OS) and 2‐year disease‐free survival (DFS) rates were 94.4% and 89.4%, respectively.

Conclusion

Neoadjuvant immunochemotherapy showed favorable efficacies, anticipated outcomes, and tolerable toxicity for patients with CMSCCUP. More clinical practice and clinical studies are still needed to confirm further.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsUterine Cervical NeoplasmsCarcinoma, Squamous CellNeoplasms, Unknown PrimaryHumansFemaleMiddle AgedRetrospective StudiesAgedAdultPaclitaxelCisplatinTreatment OutcomeImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

PD‐1 inhibitorscervical metastatic squamous cell carcinoma of unknown primaryimmunotherapyneoadjuvant therapysquamous cell carcinoma of the head and neck

Substanzen

PaclitaxelCisplatinImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • State Key Laboratory of Oncology in South China, Guangzhou, China.
  • Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
  • Department of Anesthesiology, Hospital of Stomatology, Sun Yat-Sen University, Guangzhou, China.
  • Guanghua School of Stomatology, Sun Yat-Sen University, Guangzhou, China.
  • Department of Thyroid Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, China.

ORCID-Profile: Xianlu Gao

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Gao, X., Fu, S., Yang, C., Jiang, W., Liang, J., Li, R., Yan, S., Du, M., Yang, S., Zhang, Q., & Chen, S. (2025). Evaluation of Efficacy of Neoadjuvant Immunochemotherapy for Cervical Metastatic Squamous Cell Carcinoma of Unknown Primary. Cancer Medicine. https://doi.org/10.1002/cam4.70869

Vancouver

Gao X, Fu S, Yang C, Jiang W, Liang J, Li R, et al. Evaluation of Efficacy of Neoadjuvant Immunochemotherapy for Cervical Metastatic Squamous Cell Carcinoma of Unknown Primary. Cancer Medicine. 2025. doi:10.1002/cam4.70869

BibTeX
@article{Gao2025,
  author = {Gao, Xianlu and Fu, Shuwen and Yang, Chulin and Jiang, Wenmei and Liang, Jiadong and Li, Ruiyu and Yan, Shida and Du, Mingyuan and Yang, Shiyan and Zhang, Quan and Chen, Shuwei},
  title = {Evaluation of Efficacy of Neoadjuvant Immunochemotherapy for Cervical Metastatic Squamous Cell Carcinoma of Unknown Primary},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70869}
}
Kostenlos starten →